Grace Therapeutics (GRCE) Enterprise Value (2017 - 2026)
Grace Therapeutics (GRCE) posted Enterprise Value of -$15.7 million for Q1 2026, up 10.38% sequentially from -$17.5 million in Q4 2025, and up 26.44% YoY from -$12.4 million in Q1 2025.
Grace Therapeutics (GRCE) Enterprise Value (2017 - 2026) Analysis & Trends
Grace Therapeutics has reported Enterprise Value for 10 years, with the latest figure at -$15.7 million in Q1 2026.
- Quarterly Enterprise Value rose 26.44% year-over-year to -$15.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$15.7 million (up 26.44% YoY) and the FY2026 annual result came in at -$15.7 million, up 26.44% from the prior year.
- Enterprise Value advanced to -$15.7 million in Q1 2026 per GRCE's latest filing, from -$17.5 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$14000.0 in Q3 2022 and troughed at -$43.7 million in Q1 2022.
- A 5-year average of -$15.4 million and a median of -$16.2 million in 2023 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2022 and 2023: Enterprise Value jumped 99.9% in 2022, then tumbled 117114.29% in 2023.
- Over 5 years, Enterprise Value stood at -$5.0 million in 2022, then plunged by 359.7% to -$23.1 million in 2023, then jumped by 55.67% to -$10.2 million in 2024, then sank by 71.1% to -$17.5 million in 2025, then gained by 10.38% to -$15.7 million in 2026.
- According to Business Quant data, Enterprise Value over the past three periods registered -$15.7 million, -$17.5 million, and -$15.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 2.12 Bn |
| 10 | Grace Therapeutics | 37.99 Mn | 37.99 Mn | - | -13.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -13.76 Mn |
| Mar 31, 2026 | -15.67 Mn |
| Dec 31, 2025 | -17.49 Mn |
| Sep 30, 2025 | -14.97 Mn |
| Jun 30, 2025 | -18.09 Mn |
| Mar 31, 2025 | -21.30 Mn |
| Dec 31, 2024 | -10.22 Mn |
| Sep 30, 2024 | -14.15 Mn |
| Jun 30, 2024 | -16.37 Mn |
| Mar 31, 2024 | -19.73 Mn |
| Dec 31, 2023 | -23.05 Mn |
| Sep 30, 2023 | -16.41 Mn |
| Jun 30, 2023 | -16.24 Mn |
| Mar 31, 2023 | -10.09 Mn |
| Dec 31, 2022 | -5.02 Mn |
| Sep 30, 2022 | -14,000.00 |
| Jun 30, 2022 | -16,000.00 |
| Mar 31, 2022 | -43.66 Mn |
| Dec 31, 2021 | -13.31 Mn |
| Sep 30, 2021 | -13.86 Mn |